Purpose: Automatic border detection is the first and most crucial step for lesion segmentation and can be very challenging, due to several lesion characteristics. There are many melanoma border-detecting algorithms that perform poorly on dermoscopy images of basal cell carcinoma (BCC), which is the most common skin cancer. One of the reasons for poor lesion detection performance is that there are very few algorithms that detect BCC borders, because they are difficult to segment, even for dermatologists. This difficulty is due to low contrast, variation in lesion color and artifacts inside/outside the lesion. Segmentation that has adequate lesion-feature capture, with acceptable tolerance, will facilitate accurate feature segmentation, thereby maximizing classification accuracy. Methods: The main objective of this research was to develop an effective BCC border detecting algorithm whose accuracy is better than the existing melanoma border detectors that have been applied to BCCs. Fifteen auto-thresholding techniques were implemented for BCC lesion segmentation; but, only five were selected for use in algorithm development. A novel technique was developed to automatically expand BCC lesion borders, to completely circumscribe the lesion. Two error metrics were used that better measure Type II (false-negative) errors: Relative XOR error and Lesion Capture Ratio (a novel error metric). Results: On training and test sets of 1023 and 119 images, respectively, based on two error metrics, five thresholding-based algorithms outperformed two state-of-the-art melanoma segmentation techniques, in segmenting BCCs. Five algorithms generated borders that appreciably better matched dermatologists’ hand-drawn borders which were used as the “gold standard.” Conclusion: The five developed algorithms, which included solutions for image-vignetting correction and border expansion, to achieve dermatologist-like borders, provided more inclusive and therefore, feature-preserving border detection, favoring better BCC classification accuracy, for future work.

Submitted by JACQUELINE SILVA BRITO LIMA null (jsbl.br@oi.com.br) on 2017-01-27T15:57:11Z No. of bitstreams: 1 27-01 - TESE DOUTORADO - REVISTO - Jacqueline Silva Brito Lima.pdf: 3322352 bytes, checksum: 55c7c2ba01e794edcd6cb00deb5cc30c (MD5) / Approved for entry into archive by LUIZA DE MENEZES ROMANETTO (luizamenezes@reitoria.unesp.br) on 2017-01-31T13:41:33Z (GMT) No. of bitstreams: 1 lima_jsb_dr_bot.pdf: 3322352 bytes, checksum: 55c7c2ba01e794edcd6cb00deb5cc30c (MD5) / Made available in DSpace on 2017-01-31T13:41:33Z (GMT). No. of bitstreams: 1 lima_jsb_dr_bot.pdf: 3322352 bytes, checksum: 55c7c2ba01e794edcd6cb00deb5cc30c (MD5) Previous issue date: 2016-12-21 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / O carcinoma basocelular (CBC) é a neoplasia maligna mais comum entre os homens e sua incidência está aumentando em nosso meio. Pode se manifestar como lesão nodular, superficial, esclerodermiforme, micronodular e fibroepitelioma de Pinkus. O CBC é um carcinoma de baixa mortalidade, porém com elevada morbidade devido ao potencial destrutivo local e às elevadas taxas de reincidência. As diferenças evolutivas dos diversos tipos de carcinomas basocelulares não são bem definidas. A análise de fatores de proliferação e apoptose pode subsidiar o conhecimento sobre a fisiopatologia e as diferenças evolutivas dessas lesões. A literatura revela a escassez de investigações sobre a expressão diferencial de fatores de proliferação (Ki-67) e relacionados à apoptose (p53, survivina e NF-kB-p105) dos diferentes subtipos de carcinomas basocelulares e ainda tumores recidivados. O objetivo desse estudo é avaliar a expressão de marcadores de proliferação celular e apoptose em carcinomas basocelulares dos tipos nodular, superficial, esclerodermiforme e tumores recidivados. Foram selecionados subtipos histológicos únicos, como forma de tentar compreender o comportamento dos CBCs individualmente. As lâminas desses espécimes foram submetidas ao protocolo de marcação imuno-histoquímica. Foram estudadas 100 amostras, sendo 50 unidades de epiderme normal e as demais distribuídas entre cada subtipo tumoral. O padrão de marcação de cada marcador sobre os diferentes tipos de tecidos foi avaliado a partir de modelos lineares generalizados (GLMs) seguidos de teste post-hoc de Sidak, quando necessário. Foram encontradas diferenças estatisticamente significativas (p<0,01) na imunomarcação de diferentes tipos de tecidos para os marcadores Ki-67, p53 e survivina, mas não para o marcador p105 (p=0,21). O marcador Ki-67 foi mais expresso nos esclerodermiformes que em células da epiderme e nos nodulares. A imunomarcação do p53 foi menos expressa na epiderme que nos subtipos superficiais e nas recidivas, e também menos expressa nos esclerodermiformes que em todos os outros subtipos tumorais. A survivina mostrou uma imunomarcação maior na epiderme em relação aos subtipos tumorais estudados. A comparação entre os diferentes marcadores foi avaliada pelo cieficiente de correlação de Spearman, que detectou uma correlação estatisticamente significativa (p<0,01) entre os marcadores, Ki-67 e p53 na imunomarcação dos subtipos estudados e de células da epiderme, e uma correlação entre Ki-67 e survivina quando consideramos apenas as células tumorais. Neste estudo, a expressão simultânea de marcadores permitiu a identificação de padrões de proliferação e apoptose que individualizaram comportamentos em subtipos de CBCs, em consonância com formas recidivadas, e de forma independente na epiderme. Houve diferentes padrões de correlação entre a expressão dos marcadores dos CBCs e da epiderme. / Basal cell carcinoma (BCC) is the most common malignant neoplasm among men and its incidence is increasing in our country. It can manifest as nodular, superficial, sclerodermiform, micronodular and Pinkus fibroepithelioma lesions. BCC is a low-mortality carcinoma, but with high morbidity due to local destructive potential and high rates of recurrence. The evolutionary differences of the various types of basal cell carcinomas are not well defined. The analysis of proliferation and apoptosis factors may support knowledge about the pathophysiology and evolutionary differences of these lesions. The literature reveals the scarcity of investigations on the differential expression of proliferation factors (Ki-67) and related apoptosis (p53, survivin and NF-kB-p105) of the different subtypes of basal cell carcinomas and recurrent tumors. The aim of this study is to evaluate the expression of markers of cell proliferation and apoptosis in basal cell carcinomas of the nodular, superficial, sclerodermiform and recurrent tumors. Unique histological subtypes were selected as a way to attempt to understand the behavior of individual BCCs. The slides of these specimens were submitted to the immunohistochemical labeling protocol. A total of 100 samples were studied, being 50 normal epidermal units and the others distributed between each tumor subtype. The marking pattern of each marker on the different tissue types was evaluated from generalized linear models (GLMs) followed by Sidak post-hoc test, when necessary. Statiscally significant differences (p<0,01) in the immunostaining of different tissue types were found for the Ki-67, p53 and survivin markers, but not for the p105 marker (p=0,21). The Ki-67 marker was more expressed in sclerodermiform than in epidermal and nodular cells. Immunoblotting of p53 was less expressed in the epidermis than in superficial subtypes and relapses, and also less expressed in sclerodermiform than in all other tumor subtypes. Survivin showed a greater immunostaining in the epidermis with respect to the tumor subtypes studied. The comparison between the diferent markers was evaluated by the Spearman correlation coefficient, which detected a statistically significant correlation (p<0,01) between the markers, Ki-67 and p53 in the immunoblotting of the studied subtypes and epidermal cells, and one correlation between Ki-67 and survivin when we considered only tumor cells. In this study, the simultaneous expression of markers allowed the identification of patterns of proliferation and apoptosis that individualized behaviors in subtypes of BCCs, in consonance with relapsed forms, and independently in the epidermis. There were different patterns of correlation between the expression of BCC and epidermal markers.

The human skin provides us with an excellent protective barrier and possesses a remarkable ability of constant renewal. Basal cell carcinoma is the most common type of skin cancer. The aim of this project was to verify results from an earlier study investigating the molecular differences between basal cell carcinoma (BCC) and basal cells of normal human epidermis. In that study microdissection of cell populations from BCC and basal cells of normal epidermis respectively was performed in five cases of confirmed BCC. Following RNA extraction and amplification, a gene expression analysis was performed using a 46 k human cDNA microarray. Comparison of expression profiles showed a differential expression of approximately 300 genes in BCC. An upregulation of signaling pathways previously known to be of importance in BCC development could be observed, as well as a downregulation of differentiation markers, MHC class II molecules, and proteins active in scavenging of oxygen radicals. We wanted to confirm these findings for a number of selected genes, using real time PCR. The focal point of this project was microdissection of cells from BCC and subsequent isolation of RNA. Microdissection based methods offer a possibility of selecting well defined cell populations for further analysis by using a focused laser beam. Initially tests in order to optimize the method were also performed, concerning the dehydration process and choice of slides used in microdissection. Isolation of RNA may, as we experienced, be associated with problems due to destruction of RNA by degrading enzymes.

Cancers of the human skin are divided into melanoma and non-melanoma. Being among the most commonly diagnosed cancer cases globally, non-melanoma skin cancers are comprised of basal and squamous cell carcinomas. In dermato-pathology, basal cell carcinomas (BCCs) are a frequently encountered diagnosis of skin cancer, and most cases are treated with surgical excisions. While sporadic BCC tumors appear primarily due to aging and ultra-violet exposure, the development of numerous BCCs from a young age is one of the main clinical signs in Gorlin syndrome patients. The critical driver of BCC tumor formation is the sonic hedgehog (SHH) pathway, a pivotal developmental signaling pathway that regulates organ development, cell proliferation, and tissue repair. The majority of all sporadic and syndromic BCCs exhibit mutations in two key components in this pathway, the tumor suppressor gene patched 1 (PTCH1) or the proto-oncogene smoothened (SMO), which result in aberrant pathway activation and continued transcription of SHH-dependent genes. In the last decade, SHH inhibitors have emerged as a novel treatment for advanced and metastatic BCCs. Systemic treatment with vismodegib, a potent SMO inhibitor, can effectively reduce BCC tumor burden in adult Gorlin syndrome patients. However, it is associated with chemotherapy-related adverse events, and treatment cessation results in cancer recurrence and formation of a subset of drug resistant BCCs. While aberrant SHH signaling is key, mechanisms that underlie epithelial–stromal crosstalk and reprograming of tumor metabolism can potentially converge with this pathway and promote BCC tumor development. In this study, we investigated the effects vismodegib on the morphology, behavior, and energy metabolism of human BCC cells and human dermal fibroblasts, in individual cultures as well as in co-cultures, that enabled the crosstalk between these two cell types. Computer-assisted bright-field microscopy was used to characterize cell morphology and behavior. Nuclear magnetic resonance (NMR) and metabolomics were used to determine the metabolic activity of these cells. We found that continuous crosstalk between the cells and different concentrations of vismodegib led to distinct changes in cell morphology and growth, as well as consumption of glucose, pyruvate, and glutamine and secretion of acetate, lactate, and glutamate by these cells. Deciphering tumor driver mechanisms that converge with SHH pathway and contribute to changes within the tumor microenvironment are important not only for better understanding of BCC pathobiology, but also for the development of new mechanism-based BCC therapies with improved clinical outcomes. / 2023-02-22T00:00:00Z

The urothelium is a crucial stratified epithelial barrier that protects the urinary tract. It consists of basal cells in the lower layers and intermediate and superficial cells in the luminal layer. These urothelial cells can be identified by their distinct gene expression patterns. Superficial cells are terminally differentiated, binucleated, post-mitotic cells that are responsible for the barrier function of the urothelium via the production of uroplakin proteins. Intermediate cells act as the progenitor cells for superficial cells during development, homeostasis, and after acute injury. Basal cells consist of two populations, K14-basal cells and K5-basal cells. K14- basal cells have been shown to be progenitors that can repopulate the urothelium after chronic injury and are the cells of origin that produce bladder cancer. Bladder cancer can be classified as basal subtype or luminal subtype. The basal subtype is generally immune infiltrated, aggressive, and invasive with a poor prognosis. The luminal subtype is generally immune poor, less aggressive, and non-invasive with a better prognosis compared to basal tumors. Pparg is a nuclear hormone receptor that has been described as a master regulator of adipogenesis and cellular differentiation that also carries out important anti-inflammatory functions (in part by antagonizing the NFKB pathway). Pparg is downregulated in basal subtype muscle invasive bladder cancer and amplified in luminal subtype bladder cancer. In vivo we find that Pparg is a master regulator of cell specification during urothelial development, homeostasis, regeneration, and cancer. When Pparg is ablated in the entire urothelium, Pparg KO mutants lack mature superficial cells and undergo squamous differentiation, with an expansion of the K14-basal cell population. These Pparg KO mutants also display persistent inflammation and squamous metaplasia after injury by urinary tract infection (UTI), due to unregulated NFKB signaling. However, the squamous differentiation in the Pparg KO mutants did not progress to bladder cancer. Constitutive activation of Pparg in basal cells using a novel VP16;Pparg transgenic mouse line crossed to an Krt5CreERT2 driver induces basal cells to undergo a luminal differentiation program towards post-mitotic S-cells during homeostasis. Not surprisingly, these cells did not progress to form bladder cancer on their own. Interestingly, expression of VP16;Pparg in basal cells only drives tumor formation when the basal cells are in an “activated state,” induced by 1 month of BBN treatment. In a BBN mouse model which produces basal subtype bladder cancer in wild type animals, expression of the VP16;Pparg transgene in activated basal cells drives the formation of luminal tumors with papillary morphology, suggesting that this transcription factor is a master regulator of urothelial luminal differentiation, as has been suggested from previous in vitro studies. Like their human counterparts, these VP16;Pparg luminal tumors are immune cold. Additionally, these VP16;Pparg luminal tumors have different domains; a top domain that is “luminal,” and a bottom domain that is “basal”, suggesting the luminal tumors produced by activation of Pparg are not homogenous and undergo a phenotypic shift that mimics what has previously been reported in patient-derived organoids. Understanding the molecular mechanism that drives luminal bladder cancer provides critical information in bettering our approach in diagnosing and treating MIBCs.

京都大学 / 0048 / 新制・論文博士 / 博士(人間・環境学) / 乙第12883号 / 論人博第40号 / 新制||人||169(附属図書館) / 26||論人博||40(吉田南総合図書館) / 31601 / (主査)教授 石原 昭彦, 教授 船橋 新太郎, 教授 林 達也, 准教授 神﨑 素樹, 准教授 久代 恵介 / 学位規則第4条第2項該当 / Doctor of Human and Environmental Studies / Kyoto University / DFAM

Constant neuroregeneration in adult olfactory epithelium maintains olfactory function by basal stem cell proliferation and differentiation to replace lost olfactory sensory neurons (OSNs). Understanding the mechanisms regulating this process could reveal potential therapeutic targets for stimulating adult olfactory neurogenesis under pathological conditions and aging. Ciliary neurotrophic factor (CNTF) in astrocytes promotes forebrain neurogenesis but its function in the olfactory system is unknown. Here, we show in mouse olfactory epithelium that CNTF is expressed in horizontal basal cells, olfactory ensheathing cells (OECs) and a small subpopulation of OSNs. CNTF receptor alpha was expressed in Mash1-positive globose basal cells (GBCs) and OECs. Thus, CNTF may affect GBCs in a paracrine manner. CNTF−/− mice did not display altered GBC proliferation or olfactory function, suggesting that CNTF is not involved in basal olfactory renewal or that they developed compensatory mechanisms. Therefore, we tested the effect of increased CNTF in wild type mice. Intranasal instillation of a focal adhesion kinase (FAK) inhibitor, FAK14, upregulated CNTF expression. FAK14 also promoted GBC proliferation, neuronal differentiation and basal stem cell self-renewal but had no effective in CNTF−/− mice, suggesting that FAK inhibition promotes olfactory neuroregeneration through CNTF, making them potential targets to treat sensorineural anosmia due to OSN loss.

Basal cell carcinoma is the most common form of human malignancy, and as such there are varied methods for treating its various forms. Its more advanced and aggressive forms have required both the use of and advent of therapies which offer differing safety profiles, cost, and efficacy. Two therapies which differ substantially in these respects but have overlap in their recommended use are Mohs micrographic surgery and the pharmaceutical drug vismodegib. Few studies have sought to compare the two methods using these criteria, and as vismodegib has only received FDA approval in the past ten years, it is worthwhile to explore the limitations and advantages of each therapy. In exploring previous clinical trials and retrospective studies, the two therapies are put side by side to contrast their results with their shared intended use. The general findings were that Mohs micrographic surgery remains the gold standard for the treatment of locally advanced basal cell carcinoma, and there are few demonstrable instances in which vismodegib could be deemed a more appropriate therapy. The future of vismodegib appears to be in its use as a neoadjuvant therapy for locally advanced basal cell carcinomas for which a decrease in size by vismodegib would allow for better treatment outcomes.

No description available.

INTRODUÇÃO: O carcinoma basocelular (CBC) é o tipo de câncer cutâneo mais comum no ser humano. O aparecimento de CBC na maioria das vezes se dá de forma esporádica em indivíduos que se expõem cronicamente ao sol. Eventualmente pode estar associado a síndromes, como: Bazex-Dupré- Christol, Rombo e Gorlin-Goltz. Diferente do que ocorre nas síndromes, os casos de CBCs múltiplos familiares não sindrômicos(CBCMFNS) são poucos estudados, tendo na literatura somente cinco relatos de famílias com a doença. O fenótipo é de múltiplos CBCs superficiais sem presença de outras anormalidades. Devido os CBCs esporádicos e os CBCs presentes na Síndrome de Gorlin-Goltz apresentarem mutações no gene PTCH1, possivelmente os CBCs múltiplos também estejam associados a alterações neste gene. Este gene esta localizado na região 9q22.3 possuindo 23 éxons, tem um papel importante na formação embrionária e de supressão tumoral. OBJETIVO: Análise genética dos éxons 9,11, 16, 17 e 23 do PTCH1 de oito componentes da mesma família, pertencentes a três diferentes gerações, sendo três portadores de CBCs múltiplos, e dentre estes dois suspeitos de CBCMFNS. MÉTODOS: Extração de DNA dos leucócitos do sangue periférico; PCR; clonagem dos produtos de amplificação (pGEM T Easy Vector) e seqüenciamento (Big Dye Terminator Kit). As mutações e polimorfismos encontrados foram comparados com a literatura e banco de dados de mutação do gene PTCH1 (www.cybergene.se/PATCH). RESULTADOS: Duas novas mutações foram encontradas nos pacientes suspeitos de CBCMFNS: uma frameshift nt4130(del C) e uma missense nt4261(A->G). Nos familiares foram encontradas cinco novas mutações: Em um primeiro indivíduo uma missense nt1420(G->T); em um segundo a mesma missense nt1420(G->T) e mais uma missense nt2873(C->T); em um terceiro duas frameshift nt1443 (ins T) e nt1468 (ins T), em dois outros indivíduos, irmãos, uma outra mutação missense nt4130(C->T). Foram encontradas ainda dezoito mutações, não descritas anteriormente, nos íntrons 10,15,16 e 17, algumas se repetindo em todos os indivíduos analisados. CONCLUSÃO: Pela primeira vez estão sendo descritas mutações em éxons e íntrons do gene PTCH1 em indivíduos portadores de CBCMFNS e em alguns de seus familiares. / INTRODUCTION: Basal cell carcinomas (BCC) are the most usual skin cancer that affects human beings. Sporadic BCCs are prevalent, often arising in people chronically exposed to UV radiation from the sun. Eventually BCCs may be associated to different syndroms like Bazex-Dupré-Christol, Rambo and Gorlin. Contrarily to syndromic BCCs, the cases of multiple familiar nonsydromic BCCs(MFNSBCC) have only few studies found in the literature. Only five families have been described to date with the disease. Since sporadic and Gorlin BCCs are associated to many mutations in the PTCH1 gene, we hypothesized that the multiple BCCs phenotype is also associated with mutations in this same gene. The PTCH1 tumor suppressor gene is located in the 9q22.3 chromosomal region, contains 23 exons, and has an important role in embryogenesis. OBJETIVE: To perform genetic analysis of PTCH1 exons 9, 11, 16, 17 e 23. METHODS: Eight individuals belonging to different generations from the same family were studied. Three of them bore multiple BCCs, and two of those were suspect to have MFNSBCC. DNA was extracted from blood leukocytes, submitted to PCR, and the PCR products were cloned (pGEM T Easy Vector, Promega) and sequenced (Big Dye Terminator Kit; ABI Prism 3100 sequencer; Applied Biosystems). The polymorphisms and mutations found were analyzed and compared to literature and PTCH1database (www.cybergene.se/PTCH/). RESULTS: In the patients suspect of MFNSBCC were found two new mutation: one frameshift nt4130(del C) and one missense nt4261(A->G). In the relatives were found five new mutation: Three missense nt1420(G->T); nt2873(C->T); nt4130(C->T); and two frameshift nt1443 (ins T) and nt1468 (ins T). In the introns 10,15,16 and 17 were found eighteen new mutations that were not previously reported. CONCLUSION: For the first time mutation in exons and introns of PTCH1 gene have been described in patients bore MFNSBCC and some of their relatives.